Notorium (Bromazepam)

Bromazepam enhances the activity of the neurotransmitter GABA at the GABA‑A receptor. This positive allosteric modulation increases chloride ion flow into neurons, producing an overall inhibitory effect that calms excessive brain activity and reduces anxiety.

The appropriate dose of Notorium is individualized by the prescribing clinician based on the patient’s age, clinical condition, response to therapy, and any co‑existing medical issues. Dosage regimens are not standardized in public information and should follow the prescriber’s instructions.

Safety data for bromazepam during pregnancy and lactation are limited, and the drug is generally classified as contraindicated or to be used only if the potential benefit outweighs the risk. Women who are pregnant, planning pregnancy, or breastfeeding should discuss alternatives with their healthcare provider.

To request Notorium, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Bromazepam belongs to the benzodiazepine class, offering rapid anxiolytic effects similar to other agents like diazepam or lorazepam. Compared with non‑benzodiazepine anxiolytics, it may have a shorter half‑life and a higher risk of dependence, but it is often chosen for its potency and predictable onset.

Notorium should be stored at ambient temperature, preferably below 25 °C. Keep the tablets in the original container, protect them from moisture and direct sunlight, and ensure they are out of reach of children. Do not store in bathrooms or near heat sources.

Notorium is taken orally, usually with a glass of water. The tablet should be swallowed whole and not chewed or crushed, unless otherwise directed by a healthcare professional. Administration timing (e.g., with or without food) follows the prescriber’s guidance.

Serious risks associated with bromazepam include respiratory depression, especially when combined with other depressants, the development of physical dependence or addiction, and the potential for severe withdrawal seizures if the medication is stopped abruptly. Patients should seek immediate medical attention if they experience difficulty breathing or uncontrolled seizures.

Bromazepam is contraindicated in individuals with known hypersensitivity to benzodiazepines, severe respiratory insufficiency, acute narrow‑angle glaucoma, and in patients who are currently abusing alcohol or other central nervous system depressants. Caution is also advised for the elderly, pregnant women and those with significant liver or kidney impairment.